Wright, Matthew B. http://orcid.org/0000-0002-0532-3381
Varona Santos, Javier http://orcid.org/0000-0002-6844-4500
Kemmer, Christian
Maugeais, Cyrille
Carralot, Jean-Philippe
Roever, Stephan
Molina, Judith
Ducasa, G. Michelle
Mitrofanova, Alla
Sloan, Alexis
Ahmad, Anis http://orcid.org/0000-0001-9820-2126
Pedigo, Christopher
Ge, Mengyuan
Pressly, Jeffrey
Barisoni, Laura http://orcid.org/0000-0003-0848-9683
Mendez, Armando
Sgrignani, Jacopo
Cavalli, Andrea http://orcid.org/0000-0003-4063-4502
Merscher, Sandra
Prunotto, Marco http://orcid.org/0000-0002-0203-0129
Fornoni, Alessia http://orcid.org/0000-0002-1313-7773
Funding for this research was provided by:
Florida Department of Health (9LA08)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK117599)
Article History
Received: 28 October 2020
Accepted: 6 July 2021
First Online: 2 August 2021
Competing interests
: A.F. and S.M. are inventors on pending or issued patents aimed to diagnose or treat proteinuric renal diseases. They stand to gain royalties from their future commercialization. A.F. is Chief Scientific Officer of L&F Health LLC, holds equity interests in L&F Research and is the inventor of assets developed by ZyVersa Therapeutics. ZyVersa has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin for treatment of kidney disease from L&F Research. A.F. holds equity in River 3 Renal Corporation. S.M. is a consultant for Kintai Therapeutics, Inc and holds equity interest in L&F Research. A.F. and S.M. are supported by Hoffman-La Roche and by Boehringer Ingelheim. M.P., M.W., C.K., C.M., JP.C., and S.R. were employees of Hoffmann-La Roche Ltd at the time of those experiments. The remaining authors declare no competing interests.